Home > Gastroenterology > ECCO 2022 > Novel Treatment Modalities > Filgotinib seems promising for perianal fistulising Crohn’s disease

Filgotinib seems promising for perianal fistulising Crohn’s disease

Presented By
Dr Walter Reinisch, Medical University of Vienna, Austria
Conference
ECCO 2022
Trial
Phase 2, DIVERGENCE 2
Filgotinib was associated with numerically higher response rates than placebo in participants with perianal fistulising Crohn’s disease (PFCD). In addition, the agent was well tolerated in this participant population. Further studies are warranted to confirm the encouraging results of the current, phase 2 DIVERGENCE 2 study, which was underpowered due to low enrollment during the COVID-19 pandemic. Dr Walter Reinisch (Medical University of Vienna, Austria) explained that infliximab is the only agent with demonstrated efficacy for participants with PFCD in randomised, placebo-controlled trials [1].  The current, double-blind, placebo-controlled, phase 2 DIVERGENCE 2 trial (NCT03077412) investigated the efficacy and safety of filgotinib in participants with PFCD. Filgotinib is a once-daily, oral JAK inhibitor, approved for the treatment of active UC. Participants wit...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on